Introduction
The World Health Organization (WHO) states that vaccination is the single most effective health intervention ever developed. Child immunisation coverage has improved steadily over the past few years and yet, is still heavily reliant on the hypodermic needle and syringe model. An estimated 194 million infants do not receive basic vaccination [1] . Moreover, needle-stick injuries are a recurring problem, specifically within developing countries. Of the 35 million health care workers globally, approximately 2 million experience percutaneous exposure to infectious diseases each year [1] . As such, novel vaccine delivery technologies are necessitated in order to increase vaccination population coverage and reduce costs.
Microneedle (MN) arrays are micron-scale needle-like structures fabricated using a variety of methods, onto a supporting platform. Upon insertion into the skin, the MNs pierce the stratum corneum (SC), penetrating to the deeper skin layers. Different MN array types have been described in the literature, however dissolving MNs have received particular attention for vaccination purposes [2] . Dissolving MNs offer numerous advantages over the conventional hypodermic needle, including targeting of skin antigen presenting cells and subsequent enhanced immune responses [3] . Furthermore, MNs offer the prospect for self-application by patients, reducing the requirement for trained health care professionals and potentially reduced costs. Extensive vaccination programs in pandemic outbreaks may also benefit from the increased coverage that could be achieved by utilising minimally invasive MN technology [4] .
While dissolving MNs have demonstrated their potential for vaccination purposes, they result in polymer deposition in the skin, the effects of which have yet to be investigated.
Hydrogel-forming MN are solid systems, that, when applied to the skin, swell upon uptake of interstitial skin fluid. Vaccine contained within an accompanying reservoir can subsequently permeate through the hydrogel structure and be delivered into the viable skin [5] . Unlike dissolving MNs, hydrogel-forming MNs can be removed intact from the skin following the vaccine dose delivery and thus, avoiding the deposition of polymer within the skin. Furthermore, the cross-link density of the MNs can be tailored to facilitate the rate and degree of swelling of the hydrogel-forming MNs. These systems are therefore "tailorable" and can be changed to suit the dosing schedule of particular vaccines, therefore expanding the potential impact this technology could have. As hydrogel-forming MN arrays contain no vaccine agents, which is instead contained within a reservoir, a simplified fabrication process may be achievable compared to dissolving MN arrays. Mass production of hydrogel-forming MN arrays and reservoirs may prove more cost effective which would have implications for industrial scale up and manufacturing.
To date there have been no published studies investigating the use of hydrogel forming MNs for vaccination purposes. Accordingly, this study tested the feasibility of utilising this approach for delivery of a model protein antigen ovalbumin (OVA). We have previously reported the successful use of dissolving MNs for vaccination purposes and as such, this system was used as a comparative control. Herein, we describe the formulation, characterisation and in vitro evaluation of a novel hydrogel-forming MN array and provide key insights into the comparative potential of dissolving and hydrogel-forming MN vaccination platforms.
Furthermore, in vivo vaccination studies were conducted to test the immunogenicity of the resultant MNs laden with OVA. Specifically, OVA vaccination using dissolving MN arrays fabricated from aqueous blends of Gantrez ® S-97 were compared with a combined system of hydrogel-forming MN arrays used in conjunction with OVA containing lyophilised reservoirs.
We report the successful generation of OVA specific IgG using both delivery platforms. To the best of our knowledge, this is the first study demonstrating the potential of hydrogel forming MNs for vaccination purposes 
Materials and Methods

Chemicals
Preparation of hydrogel-forming MN arrays
Hydrogel-forming MN arrays were produced from aqueous-polymeric mixtures of 20% w/w poly(methylvinylether co-maleic acid) (Gantrez ® S-97), 7.5% w/w poly(ethylene glocol) (PEG), molecular weight 10,000 Da, and 3% w/w of sodium carbonate. Briefly, Gantrez ® S-97 and PEG 10,000 were dissolved in water, mixed with Na2CO3 and centrifuged for 15 min at 3500 rpm. Aliquots (100 µl) of the formulation were dispensed onto pre-fabricated silicone micro-molds. The silicone micro-molds had previously been laser drilled to give a female template of MN arrays (19 x 19 MN over 0.5 cm 2 ). The micro-mould templates consisted of holes of 600 µm depth, 300 µm open diameter and interspaced by 50 µm. Following aliquote dispensing the filled molds were held within a steel pressure chamber filled with atmospheric air to 60 PSI and maintained for 15 min, facilitating needle tip filling. MN arrays were dried at 20°C for 48 h. MN arrays were crosslinked by heat (80°C) for a further 24 h, allowed to cool to room temperature and, subsequently, de-molded [5, 6, 7] .
Preparation of ovalbumin-containing lyophilised reservoirs
Lyophilised drug reservoirs containing OVA were prepared using a process previously described by our group [6] . In short, a solution of OVA in distilled water (0.5% w/w) was combined with Cryogel (10% w/w), Pearlitol (40% w/w) sodium chloride (1% w/w) and sucrose (1% w/w). The lyophilisate was mixed in a speed-mixer using a rotation speed of 3000 rpm for 60 s. Following this, the lyophilisate was sonicated at 37°C for 60 min. This lyophilisate was aliquoted (250mg) into cylindrical molds (diameter 10 mm & depth 5 mm) and frozen to −80°C for a minimum of 60 min. Lyophilisation parameters were −40°C for 48 h (primary drying) ramped to 20°C for 10 h (secondary drying) with a continuous vacuum pressure of 50 mTorr.
Preparation of ovalbumin-containing dissolving microneedle arrays
Dissolving MN arrays containing Gantrez hydration. An equal quantify/amount of OVA solution was added to 40% w/w Gantrez ® and these were mixed using a glass rod to achieve a final mixture of Gantrez ® S-97 and OVA, 20% w/w and 1.25% w/w, respectively. The formulation was centrifuged (15 mins at 3500 rpm) and aliquoted to pre-fabricated silicone micro-molds with the geometry described in figure 1.
Dissolving MN arrays were dried at 20°C for 48 h and de-molded. 
OVA-specific ELISA
To analyse OVA from in vitro permeation studies, an OVA-specific ELISA was developed.
Briefly, mouse monoclonal anti-OVA (2.5 µg/ml) in 0.1 M bicarbonate buffer (pH 9.6) was prepared. Aliquots of 50 µl of the diluted anti-OVA antibody were incubated overnight at 4°C and washed 5 times with washing buffer (Tween-20 0.05% (v/v) in PBS (PBST)). The plate was blocked with SuperBlock ® T20 (150 µl/well) and incubated for 2 h at room temperature.
After washing with PBST, 50 µl aliquots of OVA solution (range: 1000 ng/ml to 100 ng/ml) were dispensed in triplicate, incubated for 1 h at room temperature and washed with PBST.
Rabbit anti-OVA polyclonal-biotin conjugate (1 µg/ml in SuperBlock Hydrochloric acid was used to terminate the enzymatic reaction and optical density (450 nm) data recorded using a 96-well plate spectrophotometer, (FluoStar, BMG labtech, London).
Dissolution of lyophilised reservoirs and dissolving microneedle arrays
Time taken to achieve complete dissolution of the dissolving MN arrays, lyophilised reservoirs and dissolving MN arrays was determined by placing the MN array or reservoirs into a volumetric flask with 20 ml with solution of PBS (pH 7.4). Samples were continuously stirred at 200 rpm and the time taken to achieve full dissolution was recorded.
MN mechanical characterisation and insertion studies
Our group has previously described how Parafilm M ® can be used to model the MN insertion depths upon application using manual insertion forces [8] . Briefly, eight Parafilm M ® layers were arranged one on-top the other, measuring approximately 1 mm in depth. These layers were place onto a sheet of dental wax for mechanical support. Manual insertion studies, using "thumb pressure", equating to approximately 20 N per array, was applied to each array prototype. MN penetration was assessed visually by counting the holes created on each layer, using a light microscope.
In vitro OVA permeation studies on modified Franz cell apparatus
OVA permeation studies were carried out using Franz cell apparatus, using neonatal porcine skin (excised from stillborn piglets) as the test membrane. Franz diffusion cells (model type:
FDC-400) with flat flanges and lumen diameter of 15 mm were housed within a diffusion drive console (FDCD) that supported magnetic stirring (600 rpm) and temperature regulation (37 ± 1ºC) [9] . Neonatal porcine skin was removed from the carcase using a dermatome set to 350 µm. The skin was stored at -20ºC for no longer than 1 month prior to use. Skin was shaved of hair, thawed in PBS (pH 7.4) and allowed to equilibrate to room Franz cell temperature before initiation of the experiment. Skin pieces were placed onto donor compartments using cyanoacrylate adhesive. MN were inserted into skin using manual pressure for 30 s, supported by a sheet of dental wax. Lyophilised reservoirs were placed onto a 10 µl aliquot of water on the upper surface of the MN array. A metal weight (13 g) was balanced on the lyophilised reservoir to ensure the MN arrays remained inserted over the course of the 24 h experimental test period.
Steel clamps secured the set-up and Parafilm M ® was used to reduce water loss though evaporation. Regular samples were taken throughout the experimental time and replaced with PBS (pH 7.4) pre-heated to 32ºC to maintain sink conditions. Similarly, OVA permeation from dissolving MN was conducted on the Franz cell apparatus. Hair was removed from the application sites on the mice 24 h before MN application. Electric clippers were used to remove the hair and, following this, depilatory cream (Gentle depilatory Cream, Nair™ Co., London, UK) was applied to the same area for 5 mins to remove any remaining hair. The cream was then removed using absorbent paper. A 24 h skin recovery period was observed to ensure full restoration of the skin barrier function [5, 6] .
In vivo OVA vaccination studies in Balb/c mice
To facilitate MN application, the mice were first anesthetised by intraperitoneal (IP) injection of the sedative agent's ketamine/xylaxine at 100/10 mg/kg. Two MN arrays were applied to the dorsal skin. The MN arrays were held in place by an adhesive foam boarder, with a 10 µl aliquot of water on the MN array. An OVA-containing lyophilised reservoir was then placed onto the MN array and held in situ with surgical tape for 24 h. Similarly, dissolving MN containing OVA were applied manually to a clean, dry, hair-free area on the dorsal skin of the mice. Surgical tape was wrapped around the animal's abdomen to ensure the MN remained in situ for 24 h. All MN arrays were left in situ for 24 h, after which time they were removed.
This process was repeated at day 0, 28, and 56, namely prime, boost, and second-boost respectively.
Extraction of serum
Mice were individually placed in a heat box set at 38ºC for a maximum of 5 min to facilitate tail vein dilation for blood sampling. Mice were restrained and tails were pierced with a 
Anti-OVA IgG specific ELISA
Serum samples from immunised mice were analysed for OVA-specific IgG using a commercially available ELISA kit (Alpha Diagnostic International, USA). ELISA analysis was carried out according to the manufacturer's instructions and antibody titres determined by calibrated spectroscopy (Powerwave XS, Bio-Tek Instruments Inc.) at 450 nm wavelength.
Statistical analysis
Statistical analysis was carried out using Microsoft (Mac Excel The mean ± standard deviation was calculated and calibration plots generated. Least squares linear regression and analysis of residuals was also carried out. Mann-Whitney U, ANOVA (Sidak correction) and t test's (p<0.05) were used, as appropriate, to define statistical significance.
Results
Formulation and fabrication of hydrogel-forming and dissolving MNs
Several polymers have been investigated for fabrication of dissolving MNs, including polyvinylpyrrolidone (PVP), polyvinyl alcohol (PVA) and hyaluronic acid. We have previously reported the successful formulation of dissolving MNs for vaccination purposes using Gantrez ® based polymers and as such, this polymer was selected for the experiments conducted herein [10, 11] . MNs were prepared as described, containing OVA as a model protein antigen. After MNs were removed from the moulds, they were imaged using light microscopy to confirm complete needle formation prior to further experimentation. Hydrogel-forming MNs were fabricated from formulations previously reported by our group to consistently and reliably produce MNs [12] . Representative images of such MNs are shown in Figure 2B . Consistent with the dissolving MNs, the hydrogel-forming MNs were removed from the moulds intact and fully formed needles could be visualised by light microscopy. In both cases, the arrays used within this study consisted of a 0.5 cm Figure 2C , with a light micrograph image of the internal porous structure shown in Figure 2D . The reservoirs were fully formed, removed from their moulds intact, and were robust enough to allow manual handling throughout in vitro and in vivo experiments. 
Mechanical characterisation and insertion studies of hydrogel-forming and dissolving MNs
For successful vaccination, MNs possess sufficient mechanical properties to successfully and reliably bypass the stratum corneum barrier. Accordingly, experiments were conducted to test the mechanical properties of both MN platforms using methods previously reported for analysing such parameters [8] . Compression tests using the Texture Analyser were conducted to assess the effects of application of an axial load on the heights of individual needles on both MN array types. Figure 3A shows the heights of MNs pre-and post-application using manual insertion pressure. As previously stated, the height of the needles on the array post fabrication was 497 ± 0.9 µm for the dissolving MNs and 543 ± 5.3 µm for the hydrogel-forming MNs.
The application of manual pressure resulted in a reduction in MN height, from 497 ± 0.9 µm to 491 ± 3.2 µm for the dissolving MN and 543.8 ± 5.3 µm to 538 ± 3.2 µm for the hydrogelforming MNs respectively. This resulted in a percentage reduction in MN height of approximately 6.04% (dissolving MN) and 5.68% (hydrogel-forming MN). These results are consistent with our previous work with other MN designs [11, 13] . Importantly, the MNs did not shatter during compression, nor did the needles appear to bend when examined microscopically.
The insertion properties of both MN types were also investigated to ensure MNs could consistently penetrate the validated skin model, Parafilm M ® and thus, be used for successful vaccination of mice in subsequent experiments. Moreover, for vaccination purposes, it may be important to estimate the depth of MN insertion, for targeting of skin antigen presenting cells [14] . Figure 3B 
In vitro OVA permeation studies
The dissolving MNs were formulated to contain 2. 
In vivo vaccination studies using hydrogel-forming and dissolving MNs
Dissolving and hydrogel-forming MN platforms were applied to the dorsal skin of BALB/c mice using manual pressure for 3 min and were held in situ with a foam border and surgical 
Discussion
MN technology has provided a platform for skin vaccination which has the potential to achieve effective immunisation whilst removing many of the risks and drawbacks associated with traditional hypodermic injection. As a result, polymeric MNs have become popular within the academic community; however, their success has been hampered by a lack of evidence to answer current regulatory concerns, such as the effect of polymers deposition and clearance from the body, and the influence of immune response to vaccine antigens. This study has employed industrially scalable manufacturing techniques to fabricate novel hydrogel-forming and dissolving MN platforms allowing, for the first time, a comparison of the two vaccination systems.
MN vaccination studies to date have shown that, following MN insertion, dissolution and subsequent antigen delivery, specific antibody production and the induction of robust cellular responses can be achieved [16] . However, as MN vaccination platforms progress towards commercialisation, transfer of laboratory manufacturing processes to industrial settings may prove challenging. Pertinently for dissolving MN delivery systems, it is important that biocompatible polymers, which are safe for human use, are employed. Uniformity of chain homogeneity, high levels of quality, and minimal batch-to-batch variation makes the use of synthetic polymers highly attractive to industrial processing. Our previous vaccination studies utilising poly(methylvinylether-co-maleic acid) as polymer base have focused on Gantrez ® AN-139 [10] . However, this polymer is not certified as benzene free [17] . Accordingly, more recent studies have availed of Gantrez ® S-97, also a poly(methylvinylether-co-maleic acid) polymer, and as such, this polymer was used to fabricate robust MN for the experiments conducted herein [11] . It is well known that a number of Gantrez ® products have been shown to produce adjuvant effects [18, 19] . While such adjuvant effects may prove beneficial in terms have therefore addressed such issues through developing alternative methods of manufacture referred to as two-step MNs. However, two step manufacturing methods have been described in order to overcome this particular issue [20] . OVA recovery from lyophilised reservoirs indicated that minimal loss of OVA was observed during the formulation process.
Lyophilisation is a commonly used formulation technique for protein vaccine agents and can provide a stable environment, avoiding many destabilization events present in other formulation processes and can, in some cases, circumvent the need for cold chain storage [21] .
The MN insertion studies confirm that both dissolving and hydrogel-forming MN successfully OVA confined to the needle tips themselves is available for permeation, with minimal delivery OVA from the supporting baseplate. This is concurrent with previous reported studies using dissolving MNs for protein delivery [12] .
Vaccination following a traditional prime, boost & second boost schedule was implemented in order to generate OVA-specific antibodies and provide long-term vaccine efficacy [22] . The results show significant incremental increases in anti-OVA specific IgG serum titres. The mice treated with the combined hydrogel-forming MN/ OVA-containing lyophilised reservoirs also showed incremental increases in anti-OVA specific IgG serum titres. This data supports the current theory that, as the hydrogel-forming MN array swells and absorbs interstitial fluid, the lyophilised reservoirs dissolves releasing OVA. The OVA is then free to permeate through the MN array and into the skin, for induction of subsequent immune responses [23] . have demonstrated that intradermal delivery of antigens over a longer period of time can result in higher antibody titres with further studies warranted to address such issues in polymeric MN systems [24] .
Gantrez ® S-97 has a low pH (pH 2) in solution and so it is possible that it may facilitate enhanced cell migration to the site of MN application in skin and therefore, result in an increased immune response. Vermeulen and co-workers reported that an acidic environment improved antigen uptake by dendritic cells [25] . Martinez et al. also reported that exposure (90-180 min) of dendritic cells to pH 6.5, resulted in dendritic cell maturation [26] . However, longer dendritic cell exposure to this pH resulted in the inability of dendritic cells to progress to a mature phenotype. While these studies demonstrated enhanced uptake and maturation of dendritic cells, the pH used was approximately pH 6. Following MN application, a more extreme acidic environment is created within the mouse skin which may have systemic effects.
Hydrogel-forming MN arrays, however, absorb interstitial fluid and acquire a more neutral pH, which in contrast may not provoke as extensive cell migration resulting in a lower immune response, despite the significantly higher levels of OVA delivered using the hydrogel system.
Another possible explanation for the enhanced responses observed with dissolving MN is that the potential adjuvant effects are conferred by polymer-OVA interactions. The hydrogelforming MN array platform is likely to result in OVA delivered into the skin as a free antigen with only minimal movement of polymeric material into the skin, as the hydrogel-forming MN arrays are removed fully intact. In contrast, as the polymeric chains of dissolving MN arrays dissolve into interstitial skin fluid, it is anticipated that entangled OVA-polymer particles may be released. As these OVA-polymer particles are released into the skin, antigen uptake and processing will undoubtedly be influenced by the polymer constituents. Polymeric adjuvants are widely used, with examples of polymeric nanoparticles used to enhance immune modulation [27] . Similar biocompatible polymers, such as poly(lactide), have been used for their adjuvant effect [28] . Manufacture of polymeric dissolving MN arrays should therefore be considered with this in mind.
Any potential adjuvant effects of polymeric material deposited in the skin could enhance immune responses in a positive manner. However, upon repeated exposure, the increased immune response may be detrimental and prove unacceptable for repeated administration. The exact cause of the adjuvant effect seen in this study is yet to be elucidated. The deposition of an acidic polymer such as Gantrez 
